Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) President Craig A. Wheeler sold 20,367 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $17.00, for a total transaction of $346,239.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Craig A. Wheeler also recently made the following trade(s):

  • On Thursday, August 10th, Craig A. Wheeler sold 16,953 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $16.94, for a total transaction of $287,183.82.

Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) traded up 2.09% during mid-day trading on Tuesday, hitting $17.10. 510,561 shares of the stock were exchanged. The stock has a 50 day moving average of $16.33 and a 200-day moving average of $15.51. The stock’s market cap is $1.27 billion. Momenta Pharmaceuticals, Inc. has a 52-week low of $10.75 and a 52-week high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The company had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. Equities analysts predict that Momenta Pharmaceuticals, Inc. will post ($1.15) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/05/momenta-pharmaceuticals-inc-mnta-president-craig-a-wheeler-sells-20367-shares.html.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. grew its stake in shares of Momenta Pharmaceuticals by 14.9% during the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 834 shares during the last quarter. Tortoise Investment Management LLC purchased a new stake in shares of Momenta Pharmaceuticals during the second quarter worth about $114,000. Pinebridge Investments L.P. grew its stake in shares of Momenta Pharmaceuticals by 4.3% during the second quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 363 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Momenta Pharmaceuticals during the first quarter worth about $158,000. Finally, Profund Advisors LLC grew its stake in shares of Momenta Pharmaceuticals by 13.1% during the second quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 1,530 shares during the last quarter. Institutional investors own 93.86% of the company’s stock.

MNTA has been the subject of a number of recent analyst reports. Stifel Nicolaus reiterated a “buy” rating and set a $26.00 price target on shares of Momenta Pharmaceuticals in a report on Thursday, August 3rd. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Barclays PLC lowered shares of Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $20.00 to $17.00 in a report on Monday, May 22nd. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Finally, Maxim Group set a $6.00 price target on shares of Momenta Pharmaceuticals and gave the company a “sell” rating in a report on Thursday, August 3rd. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. Momenta Pharmaceuticals has an average rating of “Hold” and an average target price of $16.63.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.